Consistent with our in vitro results, the combination-treated groups demonstrated a significant reduction in SA-β-gal activity and the levels of p21Cip1/Waf1 and p16Ink4a proteins compared to ADR-treated tumors (Figures 6F, G; Supplementary Figure S14A), indicating that TC treatment effectively reduced senescence in tumor tissues. The gene discussed is CDKN2A; the disease is neoplasm.